Phosphodiesterase type-5 inhibitors: A critical comparative analysis

EAU Update Series

Volumn 2, Issue 2, 2004, Pages 56-63

  Porst, Hartmut ^a  

^a NONE   (Germany)

Author keywords

Erectile dysfunction; Impotence; Phosphodiesterase (PDE) 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ALCOHOL; ALFUZOSIN; CIMETIDINE; CYCLIC AMP; CYCLIC GMP; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DOXAZOSIN; ERYTHROMYCIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MOLSIDOMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COITUS; COLOR VISION DEFECT; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DYSPEPSIA; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HUMAN; IC 50; INFECTION; INNERVATION; MALE; MYALGIA; PAIN; PELVIS SURGERY; PENIS ERECTION; PHARMACODYNAMICS; POPULATION RESEARCH; RHINITIS; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 8544272397     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euus.2004.03.007     Document Type: Article

References (36)

1. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms Physiol. Rev. 754 1995 725-748
2. Corbin JD, Francis SH, Webb D. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002;60,Suppl.: SB,4-11
3. Corbin J.D. Francis S.H. Pharmacology of phosphodiesterase 5 inhibitors IJCP 566 2002 453-459
4. Maurice DH. Phosphodiesterases and sexual function and dysfunction. Presented at the ISSIR Symposium "Molecular Mechanisms of Erectile Function" at the 4th Biennal Congress of ESSIR, 29 September 2001, Rome
5. Rybalkin S.D. Beavo J.A. Multiplicity within cyclic nucleotide phosphodiesterases Biochemical Society Transactions 24 1997 1005-1009
6. Küthe A. Wiedenroth A. Mägert H.J. et al. Expression of different phosphodiesterase genes in human cavernosum smooth muscle J. Urol. 165 2001 280-283
7. Rosen R.C. Riley A. Wagner G. et al. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822-830
8. Angulo, Gadau M, Fernandez A, et al. IC351 enhences NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur Urol 2001; 39 Suppl. 5: 106: 415
9. Bischoff E, Niewohner U, Haning H, et al. Vardenafil, a new PDE5 inhibitor, increases cGMP in rabbit corpus cavernosum. Int J Impotence Res 2000;12 Suppl. 3:S 67, A 24
10. Bischoff E. Personal communication. 2002
11. Baxendale RW, Wayman CP, Turner L, et al. Cellular localisation of phosphodiesterase type 11 (PDE 11) in human corpus cavernosum and the contribution of PDE 11 inhibition on nerve-stimulated relaxation. J Urol 2001; 165 No. 5 Suppl: 223, Abstr. 922
12. Blonde L. Korenman S.G. Siegel R.L. et al. Sildenafil citrate for treatment of erectile dysfunction is similarily effective in men with type 1 and type 2 diabetes mellitus Diabetes 49Suppl. 1 2000 A88
13. Kloner R.A. Brown M. Prisant L.M. et al. Effect of Sildenafil in patients with erectile dysfunction taking antihypertensive therapy Am. J. Hypertens. 14 2001 70-73
14. Rendell M.S. Rajfer J. Wicker P.A. et al. Sildenafil for treatment of erectile dysfunction in men with diabetes JAMA 2815 1999 421-426
15. Olsson A.M. Persson C.A. Efficacy and safety of Viagra® (sildenafil citrate) in men with cardiovascular disease and erectile dysfunction Urologe A 39Suppl. 1 2000 S118
16. Conti C.R. Pepine C.R. Sweeney M. Efficacy and safety of sildenafil citrate in treatment of erectile dysfunction in patients with ischemic heart disease Am. J. Cardiol. 83Suppl. 5A 1999 29C-34C
17. Rosen R, Seidman S, Menza M, et al. The efficacy and safety of Viagra® (sildenafil citrate) for the treatment of erectile dysfunction in men with comorbid depression. Poster, First international consultation on erectile dysfunction. Paris, July 1-3, 1999
18. Giuliano F. Hultling C. El Masry W.S. et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury Ann. Neurol. 46 1999 15-21
19. Schmid D.M. Schurch B. Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients Eur. Urol. 38 2000 184-193
20. Maytom M.C. Derry F.A. Dinsmore W.W. et al. A two-part pilot study of sildenafil (Viagra®) in men with erectile dysfunction caused by spinal cord injury Spinal Cord 37 1999 110-116
21. Wagner G, Maytom M, Smith MD, et al. Analysis of the efficacy of sildenafil (Viagra®) in the treatment of male erectile dysfunction in elderly patients. Poster, First international consultation on erectile dysfunction. Paris July 1-3, 1999
22. Fowler C, Miller J, Sharief M and the Sildenafil Study Group. Viagra (Sildenafil Citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 1999;46(3):497
23. Chen J. Mabjeesh N. Greenstein A. et al. Clinical efficacy of sildenafil in patients on chronic dialysis J. Urol. 165 2001 819-821
24. Bischoff E. Niewoehner U. Hanig U. et al. The inhibitory selectivity of vardenafil on bovine and human recombinant phosphodiesterase enzymes Int. J. Impotence Res. 13Suppl. 4 2001 S41 Abstr. 114
25. Saenz de Tejada I. Angulo J. Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil Int. J. Impotence Res. 13 2001 282-290
26. Gbekor E, Bethell S, Fawcett L, et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J Urol 2002; 167: No.4 Suppl.: p246 Abstr. 967
27. Bischoff E, Mondritzki T, Niewoehner U, et al. Vardenafil improved erections in rabbits longer than expected from half-life. Int J Impotence Res 2002; 14 Suppl 4: S42, P-009
28. Porst H. Rosen R. Radma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial Int. J. Impotence Res. 13 2001 192-199
29. Hellstrom W.J.G. Gittelman M. Karling G. et al. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial J. Andrology 23 2002 763-771
30. Goldstein I. Young J.M. Fischer J. et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes Diabetes Care 26 2003 1-7
31. Porst H. Padma-Nathan H. Giuliano F. et al. Efficacy of Tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial Urology 62 2003 121-125
32. Brock G.B. McMahon C.G. Chen K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses J. Urol. 168 2002 1332-1336
33. Saenz de Tejada I. Anglin G. Knight J.R. et al. Effects of tadalafil on erectile dysfunction in men with diabetes Diabetes Care 25 2002 2159-2164
34. Padma-Nathan H. Eardley I. Kloner R.A. Laties A.M. Montorsi F. 4 year update on the safety of sildenafil citrate (Viagra®) Urology 60Suppl. 2B 2002 67-90
35. Kloner R. Porst H. Mohan P. Norenberg C. Pomerantz K. Segerson T. et al. Cardiovascular safety of the selective PDE5 inihibitor vardenafil in patients with erectile dysfunction; an analysis of five placebo-controlled clinical trials Int. J. Impotence Res. 14Suppl. 4 2002 S22
36. Hatzichristou D, Carrier S, Carson C, et al. Vardenafil is efficacious in men with erectile dysfunction unresponsive to prior sildenafil therapy: Results of a phase III clinical trial-patient response with vardenafil in sildenafil nonresponders (PROVEN). Int J Impot Res 2003;15(Suppl 6):S5